{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=palbociclib&page=15", "query": { "intervention": "palbociclib", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 229, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=palbociclib&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=palbociclib&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T08:04:12.770Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06188520", "title": "A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ER+ HER2- Advanced Breast Cancer", "High-grade Serous Ovarian Cancer (HGSOC)" ], "interventions": [ { "name": "AZD8421", "type": "DRUG" }, { "name": "Camizestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 564, "start_date": "2023-12-05", "completion_date": "2027-08-04", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 4, "location_summary": "St Louis, Missouri • Providence, Rhode Island • Nashville, Tennessee + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06188520" }, { "nct_id": "NCT04693468", "title": "Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Palbociclib Isethionate", "type": "DRUG" }, { "name": "Talazoparib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2020-12-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04693468" }, { "nct_id": "NCT05384119", "title": "Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TTI-101", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Aromatase inhibitor (AI)", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tvardi Therapeutics, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-01-09", "completion_date": "2024-05-06", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 6, "location_summary": "Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05384119" }, { "nct_id": "NCT02222441", "title": "Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Palbociclib alone", "type": "DRUG" }, { "name": "Palbociclib plus Modafinil", "type": "DRUG" }, { "name": "Palbociclib plus pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 14, "start_date": "2014-10", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-02-20", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02222441" }, { "nct_id": "NCT04439201", "title": "Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2016-05-31", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439201" }, { "nct_id": "NCT06380751", "title": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "Saruparib (AZD5305)", "type": "DRUG" }, { "name": "Camizestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 788, "start_date": "2024-08-01", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06380751" }, { "nct_id": "NCT03774472", "title": "Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2018-08-20", "completion_date": "2024-04-17", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03774472" }, { "nct_id": "NCT01701375", "title": "A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Acute Leukemia", "Refractory Acute Leukemia", "High-Risk Myelodysplasia" ], "interventions": [ { "name": "PD 0332991", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2012-09", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2013-09-09", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 2, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701375" }, { "nct_id": "NCT04072952", "title": "A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Vepdegestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Estrogen Receptor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2019-09-22", "completion_date": "2026-03-05", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 16, "location_summary": "Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072952" }, { "nct_id": "NCT05564377", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Locally Advanced Malignant Solid Neoplasm", "Malignant Female Reproductive System Neoplasm", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Unresectable HER2-Negative Breast Carcinoma", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Neratinib Maleate", "type": "DRUG" }, { "name": "Nilotinib Hydrochloride Monohydrate", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2900, "start_date": "2023-04-07", "completion_date": "2030-07-01", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-17T08:04:12.770Z", "location_count": 479, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Kingman", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05564377" } ] }